Literature DB >> 11877635

The history and current status of tissue engineering: The future of pediatric surgery.

Tracy C Grikscheit1, Joseph P Vacanti.   

Abstract

Progress in the pediatric surgical treatment of numerous tissue deficits has been achieved through the relatively new field of tissue engineering. Tissue engineering has distinct advantages over native tissue or prosthetic substitution including self-repair and growth with the patient, avoiding multiple surgeries. The application of microfabrication has allowed more precision in the control of cell interactions and resulting tissue architecture. Copyright 2002 by W.B. Saunders Company.

Entities:  

Mesh:

Year:  2002        PMID: 11877635     DOI: 10.1053/jpsu.2002.30802

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  4 in total

1.  Improved in vitro cultivation of endothelial progenitor cells as basis for dermal substitutes with enhanced angiogenic capabilities.

Authors:  Gerrit Grieb; David Simons; Hannah Steinberger; Anna Vollmar; Jürgen Bernhagen; Norbert Pallua
Journal:  Langenbecks Arch Surg       Date:  2011-08-19       Impact factor: 3.445

Review 2.  Histotripsy methods in mechanical disintegration of tissue: towards clinical applications.

Authors:  Vera A Khokhlova; J Brian Fowlkes; William W Roberts; George R Schade; Zhen Xu; Tatiana D Khokhlova; Timothy L Hall; Adam D Maxwell; Yak-Nam Wang; Charles A Cain
Journal:  Int J Hyperthermia       Date:  2015-02-24       Impact factor: 3.914

3.  A multicellular approach forms a significant amount of tissue-engineered small intestine in the mouse.

Authors:  Frédéric G Sala; Jamil A Matthews; Allison L Speer; Yasuhiro Torashima; Erik R Barthel; Tracy C Grikscheit
Journal:  Tissue Eng Part A       Date:  2011-05-04       Impact factor: 3.845

4.  Engineering of three-dimensional microenvironments to promote contractile behavior in primary intestinal organoids.

Authors:  Rebecca L DiMarco; James Su; Kelley S Yan; Ruby Dewi; Calvin J Kuo; Sarah C Heilshorn
Journal:  Integr Biol (Camb)       Date:  2014-02       Impact factor: 3.177

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.